Gynaecomastia in Australia is a common benign condition characterised by the enlargement of male breast glandular tissue. It can result from an imbalance between oestrogen and androgen activity and can affect males across the lifespan, from infancy to old age. While gynaecomastia is not life-threatening, it is clinically significant due to its potential to indicate underlying disease and its considerable psychological and social impact.
Content Overview
Definition and Distinction from Pseudo gynaecomastia
True gynaecomastia refers specifically to the proliferation of glandular breast tissue in males. This tissue is typically firm or rubbery and located centrally beneath the nipple–areolar complex. It must be distinguished from pseudo gynaecomastia, which involves excess adipose tissue deposition in the chest without glandular proliferation. Pseudo gynaecomastia is increasingly common in Australia due to rising obesity rates and may coexist with true gynaecomastia.
Accurate distinction is essential, as the causes, management and prognosis differ. True gynaecomastia reflects hormonal influences, whereas pseudo gynaecomastia is primarily related to body composition.
Pathophysiology
The development of gynaecomastia can be an imbalance between oestrogens, which stimulate breast tissue growth, and androgens, which inhibit it. This imbalance can occur through several mechanisms, including increased oestrogen production, reduced testosterone production, increased peripheral conversion of androgens to oestrogens, or heightened breast tissue sensitivity to oestrogens.
In males, oestrogens are produced in small amounts by the testes and adrenal glands, with additional conversion occurring in adipose tissue via the enzyme aromatase. Any condition that increases aromatase activity or reduces androgen action can predispose an individual to gynaecomastia. Importantly, absolute oestrogen levels may remain normal; it is the relative ratio of oestrogen to testosterone that is critical.
Epidemiology and Australian Statistics
Gynaecomastia in Australia is common , with prevalence varying according to age and population group. Studies suggest that up to 60–70% of adolescent boys experience some degree of pubertal gynaecomastia. This typically occurs between the ages of 10 and 14 years and resolves spontaneously within one to two years in the majority of cases.
In adult men, the prevalence of gynaecomastia is estimated to be 30–40%, with rates increasing with age. Australian data indicate that gynaecomastia becomes more common after the age of 50, reflecting age-related declines in testosterone levels and increased rates of chronic disease and medication use.
Obesity is a significant contributing factor in Australia. A large number of Australian adult men are classified as overweight or obese, increasing the likelihood of both true and pseudo gynecomastia. Higher adipose tissue levels promote aromatisation of testosterone to oestrogen, thereby increasing breast tissue stimulation.
Types of Gynaecomastia
Gynaecomastia can be classified into physiological, pathological and drug-induced forms.
Physiological gynaecomastia occurs during three recognised life stages. Neonatal gynaecomastia results from placental transfer of maternal oestrogens and usually resolves within weeks. Pubertal gynaecomastia is common in adolescent boys due to transient hormonal fluctuations during puberty. Gynaecomastia in older men is associated with declining testosterone levels, increased fat mass and changes in sex hormone–binding globulin.
Pathological gynaecomastia is caused by underlying medical conditions that disrupt normal hormone balance. These include testicular disorders, endocrine diseases and systemic illnesses.
Drug-induced gynaecomastia is a frequent cause in Australia, particularly among older men. A wide range of commonly prescribed medications are implicated, making medication history a crucial component of assessment.
Causes of Gynaecomastia in Australia
The causes of gynaecomastia are diverse and often multifactorial. Key contributors include hormonal disorders, systemic disease, medication use and lifestyle factors.
Endocrine disorders such as hypogonadism, Klinefelter syndrome and hyperthyroidism can significantly alter androgen and oestrogen levels. Testicular failure reduces testosterone production, while certain tumours of the testes or adrenal glands may produce excess oestrogens or oestrogen-like substances.
Systemic diseases are important contributors. Chronic liver disease, which has a notable prevalence in Australia due to alcohol-related harm and viral hepatitis, impairs oestrogen metabolism and increases circulating levels. Chronic kidney disease can reduce testosterone synthesis and disrupt gonadotropin release.
Medications represent one of the most common causes of gynaecomastia in Australian clinical practice. Drugs such as spironolactone, anti-androgens, some antidepressants, antipsychotics, calcium channel blockers and medications used in prostate cancer treatment are well-recognised contributors. The increasing use of long-term medication use in Australia’s ageing population has heightened the relevance of this cause.
Substance use also plays a role. Excessive alcohol consumption can directly suppress testosterone production and damage the liver. Recreational drugs such as cannabis and the non-medical use of anabolic steroids are particularly relevant among younger males.
Clinical Presentation
Gynaecomastia usually presents as a symmetrical or asymmetrical enlargement of one or both breasts. The tissue is typically palpable as a firm, concentric mass beneath the nipple and areolar. Tenderness or pain is common in early or rapidly developing cases but may subside over time.
Beyond physical symptoms, gynaecomastia can have a profound psychological impact. Australian studies and clinical experience indicate that adolescents with gynaecomastia may experience embarrassment, bullying, reduced self-esteem and social withdrawal. Adult men may also report distress, body image concerns and reduced quality of life.
Although gynaecomastia is benign, it is essential to exclude male breast cancer, which, while rare, accounts for less than 1% of all breast cancers in Australia. Warning signs such as hard, fixed masses, nipple retraction, discharge or axillary lymphadenopathy require urgent investigation.
Diagnosis
Diagnosis begins with a comprehensive history and physical examination. Important historical features include age of onset, duration, rate of progression, pain, medication use, alcohol and drug intake, and symptoms of systemic illness.
Physical examination aims to differentiate true gynaecomastia from pseudo gynecomastia and to identify features suggestive of malignancy. Examination of the testes, thyroid and abdomen can provide valuable clues to underlying causes.
In adolescents with typical pubertal gynaecomastia, no investigations are usually required. However, further testing is indicated when gynaecomastia is pre-pubertal, rapidly progressive, unilateral, painful or persistent. Laboratory investigations may include serum testosterone, oestradiol, luteinising hormone, follicle-stimulating hormone, thyroid function tests, and liver and renal function tests.
Imaging such as breast ultrasound or mammography may be used when the diagnosis is uncertain or malignancy is suspected.
Management and Treatment for Gynaecomastia in Australia
Management of gynaecomastia in Australia depends on the underlying cause, severity and impact on the individual.
Observation and reassurance are appropriate for physiological gynaecomastia, particularly during puberty. Education about the condition’s benign and self-limiting nature is crucial and can significantly reduce anxiety.
Treatment of underlying conditions is the cornerstone of management in pathological gynaecomastia. This may involve managing endocrine disorders, treating liver or kidney disease, or modifying medication regimens where possible.
Medical therapy may be considered in selected cases, particularly when gynaecomastia is painful or psychologically distressing and of recent onset. Medications that modulate oestrogen activity can be effective when used early, though they are not routinely required.
Surgical management is an option for long-standing, severe or persistent gynaecomastia that does not respond to conservative measures. Surgical approaches include subcutaneous mastectomy with or without liposuction.
Prognosis and Outcomes
The overall prognosis for gynaecomastia is excellent. Most physiological cases resolve spontaneously, and many pathological cases improve with appropriate management. Long-standing gynaecomastia may become fibrotic and less responsive to medical therapy, but surgical outcomes are generally favourable.
While gynaecomastia does not increase mortality, its psychosocial consequences can be significant. Recognition of mental health impacts is essential, particularly in adolescents, and support should be offered when needed.
Conclusion
Gynaecomastia in Australia is a common and clinically relevant condition affecting males across all age groups in Australia. It can arise from an imbalance between oestrogen and androgen activity and may be physiological, pathological or drug-induced. Australian prevalence is high, particularly among adolescents, older men and individuals with obesity or chronic illness.
Although benign, gynaecomastia can cause considerable psychological distress and may signal underlying disease. Early recognition, appropriate assessment and patient-centred management are essential. With rising obesity rates and an ageing population, gynaecomastia in Australia will remain an important issue in health care, highlighting the need for continued education, awareness and evidence-based management.